|drug107||ARFC mask Wiki||1.00|
|drug2847||Respiratory Mechanics Wiki||1.00|
|D012127||Respiratory Distress Syndrome, Newborn NIH||0.08|
|D055371||Acute Lung Injury NIH||0.08|
|D012128||Respiratory Distress Syndrome, Adult NIH||0.07|
There is one clinical trial.
This is a multicenter randomized controlled clinical trial with an adaptive design assessing the efficacy of setting the ventilator based on measurements of respiratory mechanics (recruitability and effort) to reduce Day 60 mortality in patients with acute respiratory distress syndrome (ARDS). The CAVIARDS study is also a basket trial; a basket trial design examines a single intervention in multiple disease populations. CAVIARDS consists of an identical 2-arm mechanical ventilation protocol implemented in two different study populations (COVID-19 and non-COVID-19 patients). As per a typical basket trial design, the operational structure of both the COVID-19 substudy (CAVIARDS-19) and non-COVID-19 substudy (CAVIARDS-all) is shared (recruitment, procedures, data collection, analysis, management, etc.).
Description: The lack of an appropriate surrogate endpoint, and the high baseline mortality rate mandate a multicentre RCT to determine the mortality effects of setting the ventilator based on recruitability and effort compared with conventional ventilation.Measure: All-cause 60-day mortality Time: 60 days
Description: Duration of ventilation in daysMeasure: Duration of ventilation Time: May exceed 60 days
Description: Duration of ICU and hospital stay in daysMeasure: Duration of ICU and hospital stay Time: May exceed 60 days
Description: Organ dysfunction as per the SOFA scoreMeasure: Number of patients with organ dysfunction Time: Day 1-7, 14, 21, 28
Description: Barotrauma defined as new onset of pneumothoraxMeasure: Number of patients with barotrauma Time: Up to 60 days
Description: MortalityMeasure: Mortality at ICU discharge, 28 days, and hospital discharge Time: Up to date of ICU discharge, 28 days, and hospital discharge
Description: Biomarkers include interleukin 6 (IL-6), interleukin 8 (IL-8), tumor necrosis factor receptor 1 (TNFr1), soluble receptor of the advanced glycation end products (sRAGE), and surfactant protein D (SPD). All measured in pg/mlMeasure: The change in biomarker expression Time: Baseline, 24 and 72 hours
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports